ALX Oncology announces Phase Ib/II trial results for breast cancer

​ALX Oncology has announced new data from a Phase Ib/II clinical trial of its CD47-inhibitor, evorpacept, combined with Jazz Pharmaceuticals’ Ziihera in heavily pretreated patients with HER2-mBC.

The post ALX Oncology announces Phase Ib/II trial results for breast cancer appeared first on Hospital Management.

 

Back to the Featured Stories

Featured Stories

Philips unveils new InkSpace Snuggle coil for paediatric imaging
Lyell doses first patient in Phase III trial for LBCL
Natus Sensory acquires medical technology company TheraB Medical
MSD receives FDA approval for Keytruda combo to treat ovarian cancer
Patient enrolment concludes in Senti Biosciences’ SENTI-202 Phase I trial

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us